These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 8823232)

  • 1. Bidirectional interaction of valproate and lamotrigine in healthy subjects.
    Anderson GD; Yau MK; Gidal BE; Harris SJ; Levy RH; Lai AA; Wolf KB; Wargin WA; Dren AT
    Clin Pharmacol Ther; 1996 Aug; 60(2):145-56. PubMed ID: 8823232
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of VPA dose and concentration effects on lamotrigine pharmacokinetics: implications for conversion to lamotrigine monotherapy.
    Gidal BE; Sheth R; Parnell J; Maloney K; Sale M
    Epilepsy Res; 2003 Dec; 57(2-3):85-93. PubMed ID: 15013050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of age, weight and concomitant treatment on lamotrigine pharmacokinetics.
    Brzaković BB; Vezmar Kovačević SD; Vučićević KM; Miljković BR; Martinović ZJ; Pokrajac MV; Prostran MŠ
    J Clin Pharm Ther; 2012 Dec; 37(6):693-7. PubMed ID: 22583007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A dosing algorithm for converting from valproate monotherapy to lamotrigine monotherapy in patients with epilepsy.
    Sale ME; Natarajan S; Biton V; Vuong A; Hammer AE; Messenheimer JA; Blum D
    Epilepsy Behav; 2005 Feb; 6(1):63-70. PubMed ID: 15652736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioequivalence of generic lamotrigine 100-mg tablets in healthy Thai male volunteers: a randomized, single-dose, two-period, two-sequence crossover study.
    Srichaiya A; Longchoopol C; Oo-Puthinan S; Sayasathid J; Sripalakit P; Viyoch J
    Clin Ther; 2008 Oct; 30(10):1844-51. PubMed ID: 19014839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sodium valproate acutely inhibits lamotrigine metabolism.
    Yuen AW; Land G; Weatherley BC; Peck AW
    Br J Clin Pharmacol; 1992 May; 33(5):511-3. PubMed ID: 1524964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Valproate effects on kinetics of lamotrigine in pregnancy and treatment with oral contraceptives.
    Tomson T; Luef G; Sabers A; Pittschieler S; Ohman I
    Neurology; 2006 Oct; 67(7):1297-9. PubMed ID: 17030773
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-randomized study to investigate the effects of the atypical antipsychotic aripiprazole on the steady-state pharmacokinetics of lamotrigine in patients with bipolar I disorder.
    Schieber FC; Boulton DW; Balch AH; Croop R; Mallikaarjun S; Benson J; Carlson BX
    Hum Psychopharmacol; 2009 Mar; 24(2):145-52. PubMed ID: 19132712
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregabalin drug interaction studies: lack of effect on the pharmacokinetics of carbamazepine, phenytoin, lamotrigine, and valproate in patients with partial epilepsy.
    Brodie MJ; Wilson EA; Wesche DL; Alvey CW; Randinitis EJ; Posvar EL; Hounslow NJ; Bron NJ; Gibson GL; Bockbrader HN
    Epilepsia; 2005 Sep; 46(9):1407-13. PubMed ID: 16146435
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epilim chrono: a multidose, crossover comparison of two formulations of valproate in healthy volunteers.
    Roberts D; Easter D; O'Bryan-Tear G
    Biopharm Drug Dispos; 1996 Mar; 17(2):175-82. PubMed ID: 8907724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Time course of reversal of valproate-mediated inhibition of lamotrigine.
    Leary E; Sheth RD; Gidal BE
    Seizure; 2018 Apr; 57():76-79. PubMed ID: 29574285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neurotoxicity following addition of intravenous valproate to lamotrigine therapy.
    Burneo JG; Limdi N; Kuzniecky RI; Knowlton RC; Mendez M; Lawn N; Faught E; Welty TE; Prasad A
    Neurology; 2003 Jun; 60(12):1991-2. PubMed ID: 12821749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of a pharmacokinetic drug-drug interaction between lithium and valproate when co-administered with aripiprazole.
    Boulton DW; Kollia GD; Mallikaarjun S; Kornhauser DM
    J Clin Pharm Ther; 2012 Oct; 37(5):565-70. PubMed ID: 22943745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lamotrigine and valproate pharmacokinetics interactions in epileptic patients.
    Lalic M; Cvejic J; Popovic J; Bozic K; Golocorbin-Kon S; Al-Salami H; Mikov M
    Eur J Drug Metab Pharmacokinet; 2009; 34(2):93-9. PubMed ID: 19645218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of raltegravir on the glucuronidation of lamotrigine.
    van Luin M; Colbers A; Verwey-van Wissen CP; van Ewijk-Beneken-Kolmer EW; van der Kolk M; Hoitsma A; da Silva HG; Burger DM
    J Clin Pharmacol; 2009 Oct; 49(10):1220-7. PubMed ID: 19717722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interaction study between eslicarbazepine acetate and lamotrigine in healthy subjects.
    Almeida L; Nunes T; Sicard E; Rocha JF; Falcão A; Brunet JS; Lefebvre M; Soares-da-Silva P
    Acta Neurol Scand; 2010 Apr; 121(4):257-64. PubMed ID: 20047572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo biopharmaceutical characterisation of a new formulation containing the antiepileptic drug lamotrigine in comparison to plain and dispersible/chewable lamotrigine tablets.
    Wangemann M; Retzow A; Pohlmann-Eden B
    Arzneimittelforschung; 2005; 55(6):307-11. PubMed ID: 16032969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.